Inhibition of GSK-3β was found to be therapeutic for type 2 diabetic glomerular injury as it allows NRF2 expression and subsequent suppression of oxidative stress, thus resulting in an improvement in podocyte injury and senescence (62). This evidence concerns the gene GSK3B and type 2 diabetes mellitus.